drug

Customized Adherence Enhancement

as of 2026-07-01

Add to landscape Monitor this Compare this Ask about this

at a glance

BEHAVIORAL

Pre-approval / investigational in the US

Developed by Case Western Reserve University

2 trials in the graph

Synthesized from structured facts only — each point cited above.

Mechanism & identity

Modality

BEHAVIORAL

Indications

Investigational (via trials)

Schizophrenia Schizo Affective Disorder Patient Noncompliance Medication Adherence Patient Compliance Schizophrenia Medication Nonadherence Psychotic Disorders

Trials

Reducing the Burden of Chronic Psychotic Disorders in Tanzania (CAPACITY)

NCT04327843Phase 3Completed

Customized Adherence Enhancement Plus Long-acting Injectable Antipsychotic

NCT01152697—Completed

KOLs & investigators

Martha Sajatovic, MDKOL score 7

Facts & assertions

0 sourced

No assertions recorded for this entity.

relationships

The graph out of here

developer

Case Western Reserve University

company

trial

Reducing the Burden of Chronic Psychotic Disorders in Tanzania (CAPACITY)

PHASE3

trial

Customized Adherence Enhancement Plus Long-acting Injectable Antipsychotic

trial

indication

Schizophrenia

indication

Schizo Affective Disorder

indication

Patient Noncompliance

indication

Medication Adherence

indication

KOL

Martha Sajatovic, MD

KOL score 7

person